12:00 AM
 | 
Dec 14, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tamibarotene: Updated Phase II data

Updated data from the open-label, U.S. Phase II STAR-1 trial in 11 relapsed/refractory patients who failed treatment with all-trans retinoic acid (ATRA) and arsenic trioxide showed that 6 mg/m 2 once-daily oral tamibarotene produced a hematologic complete response in 3 patients, with 4 patients achieving a MLFS. Tamibarotene was...

Read the full 223 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >